A robust genomic-based prognostic model for the assessment ofcancer stemness and survival for patients with hepatocellularcarcinoma
作者机构:Division of Thoracic SurgeryFirst Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Zhejiang University School of MedicineHangzhou 310003China Division of Hepatobiliary Pancreatic SurgeryFirst Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China
出 版 物:《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志(英文版))
年 卷 期:2024年第23卷第1期
页 面:97-102页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金:This study was supported by a grant from the National Natural Science Foundation of China(82002927)
摘 要:To the Editor:Hepatocellular carcinoma(HCC)is an aggressive malignancy with poor long-term prognosis[1].Liver cancer stem cell(CSC)can drive the metastasis,drug resistance,and recurrence of HCC[2].The regulatory mechanisms about liver cancer stemness have been investigated,which encouraged the identification and characterization of novel prognostic and therapeutic strategies for HCC[3].